ArticleJCO global oncology2025
Geriatric Assessment: ASCO Global Guideline.
Article in JCO global oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Lung Cancer Survivorship: Challenges and Care Needs.Cancers · 2026Review
- Improving diabetes management in older adults with cancer: a quality improvement project to enhance monitoring during steroid-based systemic anti-cancer therapy.European geriatric medicine · 2026Article
- Turkish Cross-Cultural Adaptation of the BRIEF-MPI in Older Adults with Cancer: Convergent and Discriminative Validity Compared with the G8 and Clinical Frailty Scale.Healthcare (Basel, Switzerland) · 2026Article
- Exploring the understanding and management of anxiety from cancer in Latino/a older adults and their caregivers.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- A survey among geriatricians on geriatric oncology and geriatric surgical oncology models in Europe.European geriatric medicine · 2026Article
- Article
- Anlotinib Plus Immune Checkpoint Inhibitors versus Chemotherapy in Elderly Patients with Extensive-Stage Small-Cell Lung Cancer: A Real World, Exploratory Study.Drug design, development and therapy · 2026Article
- Use of comprehensive geriatric assessment among oncologists in Uruguay: perceptions, practices and barriers.Ecancermedicalscience · 2026Article
- Management of brain metastases in older adults with non-small cell lung cancer.Frontiers in oncology · 2026Review
- Complementary and Alternative Therapy Use Among Cancer Patients in Qassim: Patterns, Predictors, and Patient Perspectives.Cancer management and research · 2026Article
- Efficacy and safety of PARP inhibitor maintenance therapy in elderly ovarian cancer patients: a real-world single-center retrospective cohort study.Frontiers in oncology · 2026Article
- Real-world efficacy and safety of pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma: a multi-institutional retrospective study.Scientific reports · 2025Article
- Exercise During Chemotherapy Treatment as an Adjuvant Programme in Patients With Lymphoma (EDONOLA): Study Protocol for a Randomised Controlled Trial.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
purposeTo guide clinicians and policymakers in global resource-constrained settings to assess the geriatric needs of patients older than 65 years with cancer when Maximal-setting guideline-recommended resources are unavailable.
methodsA multidisciplinary, multinational Expert Panel reviewed existing ASCO guidelines and conducted modified ADAPTE and formal consensus processes.
resultsAn ASCO resource-neutral guideline was adapted for resource-constrained settings, informing one round of formal consensus; recommendations received ≥75% agreement. RECOMMENDATIONS: The Expert Panel endorses the Maximal-setting guideline's overarching recommendation that end users utilize geriatric assessment (GA), including essential domains, to identify "vulnerabilities or impairments not routinely captured in oncology assessment for all older patients over 65 years old with cancer." All care plans for patients with cancer over 65 years old receiving systemic therapy with GA-identified deficits should include GA-guided management. A geriatric evaluation should at a minimum include the use of a brief geriatric screening tool. Tools in the Practical Geriatric Assessment (PGA) are validated in multiple languages, but users may use more appropriate tools in some settings and languages, if they include the relevant guideline-specified domains. Maximal-resource settings of high-income countries have traditionally developed cutoffs for GA-identified deficits, but locally validated research and practice may inform differing cutoffs. If validated all-cause mortality prognosis tools do not adequately represent the setting, clinicians may use actuarial life-expectancy tables with quartiles of overall health status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.